Department of Surgery and Organ Transplantation, Faculty of Medicine, Gaziosmanpasa Hospital, Istanbul Yeni Yuzyil University Istanbul, Turkey.
Eur Rev Med Pharmacol Sci. 2024 Jun;28(11):3752-3760. doi: 10.26355/eurrev_202406_36380.
End-stage liver disease is commonly associated with portal vein thrombosis (PVT). Lastly, PVT is no longer an absolute contraindication for liver transplantation, and many centers adopt portal vein thrombectomy. PVT imposes special technical difficulties during living donor liver transplantation (LDLT). In this research, the experience with PVT cases during LDLT in a high-volume center is introduced.
Between January 2018 and July 2023, 312 patients underwent LDLT. After 88 cases were excluded, 224 cases were included, and their incidence of pre-transplant PVT was 16.5% (37/224). Demographic and clinical features, perioperative variables, and post-transplant outcomes of patients with PVT (PVT group, n=37) were compared to patients who had no PVT (non-PVT group, n=187).
According to Yerdel classification, 16, 16, 2, and 3 patients had PVT grade I, II, III, and IV, respectively. Complete venous thrombectomy was accomplished in 34 patients, while for three patients, thrombectomy was not feasible, and graft inflow was established by interposition vascular graft. For portal flow modulation, splenectomy and splenic artery ligation were performed in 7 and 4 patients, respectively, while two patients underwent post-transplant splenic artery embolization. The PVT group had longer operation time (p<0.001), longer warm ischemia time (p=0.031), longer anhepatic phase (p<0.001), and intraoperatively required more than 3 packed RBCs units (p=0.029) and ≥1 platelet unit transfusion (p=0.021) than the non-PVT group. No statistically significant difference was found between groups in terms of re-exploration (p=0.954), post-transplant PVT (p=0.375), biliary (p=0.253) and arterial complications (p=0.593), ICU stay (p=0.633), hospital stay (p=896), and 30-day mortality (p=1.000). Survival analysis showed no statistically significant difference regarding 1-year survival (p=0.176) between both groups.
This study showed that patients with different stages of PVT can successfully undergo LDLT in experienced centers and that they do not differ from patients without PVT in terms of post-transplant complications.
终末期肝病常伴有门静脉血栓形成(PVT)。最后,PVT 不再是肝移植的绝对禁忌证,许多中心采用门静脉血栓切除术。在活体肝移植(LDLT)中,PVT 会带来特殊的技术难题。本研究介绍了在高容量中心进行 LDLT 时 PVT 病例的经验。
2018 年 1 月至 2023 年 7 月,312 例患者接受 LDLT。排除 88 例后,共纳入 224 例,其中术前 PVT 发生率为 16.5%(37/224)。比较 PVT 患者(PVT 组,n=37)与无 PVT 患者(非 PVT 组,n=187)的人口统计学和临床特征、围手术期变量和移植后结局。
根据 Yerdel 分类,16、16、2 和 3 例患者分别为 PVT Ⅰ级、Ⅱ级、Ⅲ级和Ⅳ级。34 例患者成功进行了完全静脉血栓切除术,3 例患者因血栓切除术不可行,通过置入血管移植物建立了移植物流入。为了调节门静脉血流,7 例患者行脾切除术和脾动脉结扎术,4 例患者行脾动脉栓塞术。PVT 组的手术时间更长(p<0.001),热缺血时间更长(p=0.031),无肝期更长(p<0.001),术中需要输注超过 3 个单位的浓缩红细胞(p=0.029)和输注≥1 个单位的血小板(p=0.021)。两组在再次探查(p=0.954)、移植后 PVT(p=0.375)、胆道(p=0.253)和动脉并发症(p=0.593)、重症监护病房停留时间(p=0.633)、住院时间(p=0.896)和 30 天死亡率(p=1.000)方面无统计学差异。生存分析显示两组患者 1 年生存率无统计学差异(p=0.176)。
本研究表明,不同阶段 PVT 的患者可在经验丰富的中心成功接受 LDLT,且与无 PVT 的患者在移植后并发症方面无差异。